DeutschNewstral
Article
bizjournals.com on 2019-06-25 17:39
Acer Therapeutics stock plummets 80 percent on FDA rejection
Related news
- MAcer Therapeutics receives CRL from FDA for Edsivo, stock halted for newsmarketwatch.com
- MPTC Therapeutics stock plummets 29% after FDA denies company's DMD drug appealmarketwatch.com
- Newton drugmaker Acer cuts more than two dozen staff after FDA rejectionbizjournals.com
FDA Approves Sage Therapeutics’ Zulressowsj.com- United Therapeutics scores another FDA approvalbizjournals.com
FDA OKs United Therapeutics’ cancer drugthedailyrecord.com- Cempra's stock down over FDA rejectionbizjournals.com
- United Therapeutics’ 2020 plan: ‘No fewer’ than 3 FDA approvalsbizjournals.com
- United Therapeutics just earned a long-awaited FDA approvalbizjournals.com
Sapience Therapeutics ST-36 receives orphan drug designation from FDAwestfaironline.com- FDA approves Spark Therapeutics' gene therapy treatment; pricing questions remainbizjournals.com
- MSarepta Therapeutics shares dive on safety issues in FDA databasemarketwatch.com
- MFate Therapeutics stock up 11% after FDA clears IND applicationmarketwatch.com
- DFDA fast-tracks Intensity Therapeutics’ breast cancer treatmentdailyvoiceplus.com
- Cincinnati Children’s spinout, Airway Therapeutics, receives key FDA approvalbizjournals.com
- United Therapeutics gets another FDA approval for pulmonary hypertension therapybizjournals.com
FDA Accepts Outlook Therapeutics’ BLA for Ophthalmic Bevacizumabjdsupra.com- FDA approves Mahana Therapeutics' controversial digital treatment for IBSbizjournals.com